新辅助治疗适用于三阴性 cT1N0 乳腺癌吗？

IF 0.2 Q4 OBSTETRICS & GYNECOLOGY

Revista de Senologia y Patologia Mamaria Pub Date : 2024-07-30 DOI:10.1016/j.senol.2024.100613

Esmeralda García-Torralba , Noel Blaya Boluda , María Esperanza Guirao García , Elisa García Garre , Francisco Ayala de la Peña

{"title":"新辅助治疗适用于三阴性 cT1N0 乳腺癌吗？","authors":"Esmeralda García-Torralba , Noel Blaya Boluda , María Esperanza Guirao García , Elisa García Garre , Francisco Ayala de la Peña","doi":"10.1016/j.senol.2024.100613","DOIUrl":null,"url":null,"abstract":"<div><p>Triple negative breast cancer (TNBC) is the most aggressive subtype, including early BC. Neoadjuvant chemotherapy (NAC) has shown benefit in achieving more conservative surgeries, but also it is useful to determine therapeutic sensitivity, prognostic estimation, and consequent choice of an individualized adjuvant treatment. Traditionally, NAC was indicated in patients with cT2 (2 cm or more) TNBC. However, recent guidelines consider neoadjuvant treatment for cT1 TNBC patients. In this paper, we review the current evidence on neoadjuvant treatment in cT1 TNBC patients, including available signals on efficacy, choice of optimal regimen and identification of patients with the greatest potential benefit.</p></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"37 4","pages":"Article 100613"},"PeriodicalIF":0.2000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is neoadjuvant treatment indicated in triple negative cT1N0 breast cancer?\",\"authors\":\"Esmeralda García-Torralba , Noel Blaya Boluda , María Esperanza Guirao García , Elisa García Garre , Francisco Ayala de la Peña\",\"doi\":\"10.1016/j.senol.2024.100613\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Triple negative breast cancer (TNBC) is the most aggressive subtype, including early BC. Neoadjuvant chemotherapy (NAC) has shown benefit in achieving more conservative surgeries, but also it is useful to determine therapeutic sensitivity, prognostic estimation, and consequent choice of an individualized adjuvant treatment. Traditionally, NAC was indicated in patients with cT2 (2 cm or more) TNBC. However, recent guidelines consider neoadjuvant treatment for cT1 TNBC patients. In this paper, we review the current evidence on neoadjuvant treatment in cT1 TNBC patients, including available signals on efficacy, choice of optimal regimen and identification of patients with the greatest potential benefit.</p></div>\",\"PeriodicalId\":38058,\"journal\":{\"name\":\"Revista de Senologia y Patologia Mamaria\",\"volume\":\"37 4\",\"pages\":\"Article 100613\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista de Senologia y Patologia Mamaria\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0214158224000410\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Senologia y Patologia Mamaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214158224000410","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

三阴性乳腺癌（TNBC）是侵袭性最强的亚型，包括早期 BC。新辅助化疗（NAC）在实现更保守的手术方面已显示出其优势，但它也有助于确定治疗敏感性、预后评估以及随后的个体化辅助治疗选择。传统上，NAC 适用于 cT2（2 厘米或以上）TNBC 患者。然而，最近的指南考虑对 cT1 TNBC 患者进行新辅助治疗。在本文中，我们回顾了目前有关 cT1 TNBC 患者新辅助治疗的证据，包括现有的疗效信号、最佳治疗方案的选择以及潜在获益最大的患者的确定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Is neoadjuvant treatment indicated in triple negative cT1N0 breast cancer?

Triple negative breast cancer (TNBC) is the most aggressive subtype, including early BC. Neoadjuvant chemotherapy (NAC) has shown benefit in achieving more conservative surgeries, but also it is useful to determine therapeutic sensitivity, prognostic estimation, and consequent choice of an individualized adjuvant treatment. Traditionally, NAC was indicated in patients with cT2 (2 cm or more) TNBC. However, recent guidelines consider neoadjuvant treatment for cT1 TNBC patients. In this paper, we review the current evidence on neoadjuvant treatment in cT1 TNBC patients, including available signals on efficacy, choice of optimal regimen and identification of patients with the greatest potential benefit.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista de Senologia y Patologia Mamaria Medicine-Obstetrics and Gynecology

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

63 days